X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ORCHID PHARMA LTD - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ORCHID PHARMA LTD DISHMAN PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 25.1 -0.7 - View Chart
P/BV x 3.3 0.5 713.8% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ORCHID PHARMA LTD
Sep-13
DISHMAN PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs374194 193.0%   
Low Rs12935 368.3%   
Sales per share (Unadj.) Rs197.8276.5 71.5%  
Earnings per share (Unadj.) Rs21.2-79.2 -26.8%  
Cash flow per share (Unadj.) Rs34.7-43.5 -79.9%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.953.9 333.5%  
Shares outstanding (eoy) m80.6970.45 114.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.30.4 307.2%   
Avg P/E ratio x11.9-1.4 -820.9%  
P/CF ratio (eoy) x7.2-2.6 -275.0%  
Price / Book Value ratio x1.42.1 65.9%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3068,067 251.7%   
No. of employees `0000.82.8 29.6%   
Total wages/salary Rs m5,3552,527 211.9%   
Avg. sales/employee Rs Th19,252.76,956.1 276.8%   
Avg. wages/employee Rs Th6,459.5902.5 715.7%   
Avg. net profit/employee Rs Th2,064.1-1,993.0 -103.6%   
INCOME DATA
Net Sales Rs m15,96119,477 81.9%  
Other income Rs m265407 65.2%   
Total revenues Rs m16,22619,884 81.6%   
Gross profit Rs m4,1031,103 372.1%  
Depreciation Rs m1,0912,519 43.3%   
Interest Rs m9445,227 18.1%   
Profit before tax Rs m2,334-6,236 -37.4%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m624-125 -498.1%   
Profit after tax Rs m1,711-5,580 -30.7%  
Gross profit margin %25.75.7 454.1%  
Effective tax rate %26.72.0 1,331.1%   
Net profit margin %10.7-28.7 -37.4%  
BALANCE SHEET DATA
Current assets Rs m11,01811,014 100.0%   
Current liabilities Rs m9,51732,060 29.7%   
Net working cap to sales %9.4-108.1 -8.7%  
Current ratio x1.20.3 337.0%  
Inventory Days Days11095 116.5%  
Debtors Days Days3534 103.8%  
Net fixed assets Rs m16,30429,440 55.4%   
Share capital Rs m161705 22.9%   
"Free" reserves Rs m12,9072,043 631.9%   
Net worth Rs m14,5163,800 382.0%   
Long term debt Rs m4,1899,018 46.5%   
Total assets Rs m29,80546,510 64.1%  
Interest coverage x3.5-0.2 -1,797.3%   
Debt to equity ratio x0.32.4 12.2%  
Sales to assets ratio x0.50.4 127.9%   
Return on assets %8.9-0.8 -1,172.2%  
Return on equity %11.8-146.9 -8.0%  
Return on capital %17.5-3.7 -469.4%  
Exports to sales %24.837.9 65.4%   
Imports to sales %3.722.6 16.5%   
Exports (fob) Rs m3,9567,378 53.6%   
Imports (cif) Rs m5964,406 13.5%   
Fx inflow Rs m4,9527,513 65.9%   
Fx outflow Rs m6975,649 12.3%   
Net fx Rs m4,2551,865 228.2%   
CASH FLOW
From Operations Rs m2,7861,682 165.7%  
From Investments Rs m-1,529-9,860 15.5%  
From Financial Activity Rs m-9416,644 -14.2%  
Net Cashflow Rs m316-1,535 -20.6%  

Share Holding

Indian Promoters % 61.4 32.3 190.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 4.6 80.4%  
FIIs % 12.7 3.3 384.8%  
ADR/GDR % 0.0 4.6 -  
Free float % 22.1 55.3 40.0%  
Shareholders   46,261 84,811 54.5%  
Pledged promoter(s) holding % 35.8 54.9 65.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   VENUS REMEDIES  MERCK LTD  NOVARTIS  J.B.CHEMICALS  SHASUN PHARMA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Higher; Realty & Pharma Stocks Lead(09:30 am)

Asian stock indices are trading mixed today. The Shanghai Composite is lower by 0.29% while the Hang Seng is even. The Nikkei 225 is trading higher by 0.46%.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS